Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy. Amin, A., Milhem, M. M., Long, G. V., Hoimes, C. J., Medina, T., Conry, R., Lao, C. D., Daniels, G. A., Reddy, S. A., Andtbacka, R., Barve, M. A., Shaheen, M. F., Tueting, T., Chisamore, M., Schmidt, E. V., Candia, A., Obiozor, C., Gamelin, E., Janssen, R., Ribas, A. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.15_suppl.9555

View details for Web of Science ID 000487345806609